Collegium Pharmaceutical (COLL) EPS (Basic) (2014 - 2026)

Collegium Pharmaceutical's EPS (Basic) history runs 13 years deep, the most recent figure standing at $0.45 for Q1 2026.

• On a quarterly basis, EPS (Basic) rose 494.26% year-over-year to $0.45 in Q1 2026; TTM through Mar 2026 was $2.34, a 69.19% increase from a year earlier, with the FY2025 full-year figure at $1.98, down 7.51% from the prior year.
• EPS (Basic) eased to $0.45 in Q1 2026 per COLL's latest filing, from $0.54 in the prior quarter.
• Across five years, EPS (Basic) topped out at $1.0 in Q3 2025 and bottomed at -$0.51 in Q1 2023.
• The 5-year median for EPS (Basic) is $0.38 (2025), against an average of $0.31.
• Across the five-year window, EPS (Basic) slumped 180.61% in 2022 and soared 4457.19% in 2023, its largest moves.
• Year by year, EPS (Basic) stood at -$0.21 in 2022, then soared by 544.83% to $0.95 in 2023, then slumped by 58.97% to $0.39 in 2024, then jumped by 37.74% to $0.54 in 2025, then retreated by 15.56% to $0.45 in 2026.
• Per Business Quant, the three latest COLL EPS (Basic) figures stand at $0.45 (Q1 2026), $0.54 (Q4 2025), and $1.0 (Q3 2025).